The Thrombin-activatable fibrinolysis inhibitor (TAFI), also designated procarboxypeptidase B2 or procarboxypeptidase U, is a hepatically secreted zymogen that downregulates fibrinolysis when activated by Thrombin.
It is synthesized in the liver and circulates in plasma in its proenzyme form.
When activated, TAFI removes C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins.
TAFI cleaves the lysine residues from Fibrin, which prevents plasminogen from activation into plasmin and retards the lysis of a Fibrin clot.
Elevated concentration of TAFI in blood is considered a risk factor for venous thrombosis, whereas a deficiency might contribute to the severity of bleeding disorders in hemophilias A and B.
Decreased levels of TAFI are found in chronic liver disease.
Applications:Suitable for use in Western Blot, Immunohistochemistry.
Other applications not tested.
Recommended Dilution:Western Blot: 1:500-1:2000Immunohistochemistry: 1:50-1:200Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months after receipt.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：50ul
Host：rabbit
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by immunoaffinity chromatography.
Form：Supplied as a liquid PBS, 0.1% sodium azide, 50% glycerol.
Specificity：Recognizes endogenous levels of CPB2. Species Crossreactivity: Human, mouse, rat
